Trials

ANZGOG unveils 2023-2028 Strategic Plan – Advancing Research, Saving Lives

Introducing our new strategic plan, a five-year roadmap that will advance the excellence and impact of our gynaecological cancer research. In May 2023, a group of 24 ANZGOG members gathered to discuss the organisation's values, [...]

ANZGOG unveils 2023-2028 Strategic Plan – Advancing Research, Saving Lives2023-08-30T12:18:29+10:00

PARAGON – the study that drove ANZGOG’s position at the forefront of innovative trial designs

Led by ANZGOG co-founder Professor Michael Friedlander AM, PARAGON was one of ANZGOG's first practice-changing studies. The publications arising from the insights and data collected because of this pivotal trial continue to contribute to research on [...]

PARAGON – the study that drove ANZGOG’s position at the forefront of innovative trial designs2023-10-18T11:45:30+11:00

ITTACc – ANZGOG’s latest cervical cancer study, incorporating ANZGOG’s first teletrial cluster!

A Phase II Trial of Tislelizumab in combination with Sitravatinib for Recurrent/Metastatic Cervical Cancer after Platinum-Based Chemotherapy. The ITTACc study is an ANZGOG-developed trial led in Australia by A/Prof Jeffrey Goh from the Royal [...]

ITTACc – ANZGOG’s latest cervical cancer study, incorporating ANZGOG’s first teletrial cluster!2023-10-18T11:49:12+11:00

ANZGOG’s Endometrial Cancer Study Awarded $1.27 Million in Funding from the MRFF Grant

ANZGOG’s TAPER Study has received $1.27 million in funding from the Australian Government’s Medical Research Future Fund (MRFF) which aims to improve the health and wellbeing of Australians by supporting medical research and innovation.  [...]

ANZGOG’s Endometrial Cancer Study Awarded $1.27 Million in Funding from the MRFF Grant2023-10-18T11:50:42+11:00
Go to Top